Shield Therapeutics PLC Total Voting Rights (1076A)

TIDMSTX

RNS Number : 1076A

Shield Therapeutics PLC

28 May 2021

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Total Voting Rights Update

London, UK, 28 May 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer(R) (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 215,885,024 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

 
 Shield Therapeutics plc                                                 [phone] 
 Tim Watts (CEO) 
  Lucy Huntington-Bailey (Company Secretary 
  and General Counsel) 
 
 Peel Hunt LLP - Nominated Adviser & Joint 
  Broker                                                                 [phone] 
 James Steel / Christopher Golden 
 
 finnCap Ltd - Joint Broker                                              [phone] 
 Geoff Nash / Alice Lane / Matthew 
  Radley 
 
 Walbrook PR - Financial PR & IR Adviser                                 [phone] 
 Paul McManus / Lianne Cawthorne                                     or [e-mail] 
 
 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R) /Accrufer(R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer(R) in the US during 2021 through a highly experienced sales and marketing team. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRPPUCPAUPGGMM

(END) Dow Jones Newswires

May 28, 2021 02:00 ET (06:00 GMT)